期刊
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
卷 8, 期 11, 页码 924-933出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2010.06.032
关键词
Hepatitis C Virus; Burden of Disease; Hepatic Comorbidities; Prevalence
资金
- Vertex Pharmaceuticals Incorporated
- Human Genome Science Merck Roche
- Schering Plough
- Vertex Pharmaceuticals
- Roche
Hepatitis C virus (HCV) infections pose a growing challenge to health care systems Although chronic HCV infection begins as an asymptomatic condition with few short term effects, it can progress to cirrhosis, hepatic decompensation, hepatocellular carcinoma (HCC), and death The rate of new HCV infections is decreasing, yet the number of infected people with complications of the disease is increasing In the United States, people born between 1945 and 1964 (baby boomers) are developing more complications of infection Men and African Americans have a higher prevalence of HCV infection Progression of fibrosis can be accelerated by factors such as older age, duration of HCV infection, sex, and alcohol intake Furthermore, insulin resistance can cause hepatic steatosis and is associated with fibrosis progression and inflammation If more effective therapies are not adopted for HCV, more than 1 million patients could develop HCV related cirrhosis, hepatic decompensation, or HCC by 2020, which will impact the US health care system It is important to recognize the impact of HCV on liver disease progression and apply new therapeutic strategies
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据